ARTICLE | Deals
Deals Report: Novartis-Generate use AI to develop protein therapies, and updates from Roche-Regor, CSPC-Alphamab and more
By Gunjan Ohri, Data Content Analyst, and Paul Bonanos, Director of Biopharma Intelligence
October 1, 2024 1:21 AM UTC
With its cash reserves dwindling, Prime Medicine has struck a deal with BMS to deploy its technology in ex vivo T cell therapies, padding its balance sheet as it narrows its pipeline to three key programs in rare diseases.
Prime Medicine Inc. (NASDAQ:PRME) will receive $110 million up front in Monday’s deal with Bristol Myers Squibb Co. (NYSE:BMY), with half coming as an equity investment. BMS will have rights to use Prime’s reagents, including some with its non-viral large cargo PASSIGE technology, in cell therapies across multiple therapeutic areas including oncology and immunology…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653731/prime-narrows-gene-editing-focus-with-bms-deal